Ligand Pharmaceuticals stock expands royalty pipeline with USD 47.00 million deal

Published on 10/01/2026 at 00:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ligand Pharmaceuticals stock added up to USD 41.00 million in royalty financing on September 24, 2026. Q2 revenue reached USD 63.69 million and GAAP EPS was USD 2.22.

LGND, US53220K1060, Illustration mit AI erstellt.

Ligand Pharmaceuticals (ISIN US53220K1060) committed up to USD 47.00 million to an AvenCell financing agreement dated September 24, 2026, broadening its exposure to early-stage cell therapies. The filing gives Ligand rights to royalties on AvenCell's current and future pipeline assets, while the clinical programs remain dependent on development and regulatory progress.

Royalty financing reaches USD 41.00 million

According to StockTitan, the agreement dated September 24, 2026 includes up to USD 41.00 million in royalty financing and up to USD 6.00 million in Series C funding. The capital is split into four tranches, with later payments tied to clinical milestones and other financing conditions.

The royalty rate is described as mid-single-digit to low-double-digit on worldwide annual net sales from AvenCell's pipeline. Its lead program, AVC-201, is in a Phase 1b expansion trial for relapsed or refractory acute myeloid leukemia, while AVC-203 is in a Phase 1a program for B-cell malignancies.

Q2 revenue rose 33.80 percent

Ligand's latest reported quarter also provides a measurable operating comparison. In Q2 2026, revenue was USD 63.69 million, up 33.80 percent year over year, while adjusted EPS was USD 2.37 against a USD 1.97 consensus estimate, according to MarketBeat on September 28, 2026. GAAP diluted EPS was USD 2.22, and GAAP net income reached USD 48.51 million for the same period.

The company also set fiscal 2026 adjusted EPS guidance at USD 9.00-9.50. That forecast gives the AvenCell deal a strategic role, but its eventual financial contribution depends on clinical milestones, future funding and commercial sales.

Market value stands at USD 6.3 billion

Ligand's market capitalization was USD 6.3 billion as of September 30, 2026. The 52-week range stood at USD 175.56 to USD 326.63, placing the current valuation against a wide biotechnology trading history rather than a single product catalyst.